Amid takeover chatter, Biogen introduces hemophilia spinoff Bioverativ


Biogen’s introducing investors to its hemophilia spinoff--and the company may be hoping it’ll take some attention away from recent buyout buzz, too.

On Tuesday, the Massachusetts biotech said it would dub the to-be-jettisoned business Bioverativ--a name that “creates a clear connection to our Biogen heritage and biotech focus,” John Cox, future CEO of the new company, said in a statement. The new company's shares will trade on the Nasdaq exchange under the symbol BIVV.

The news follows a flurry of M&A rumors about potential buyout interest from Allergan, Merck, and others. But Biogen isn’t soliciting offers, follow-up reports have said--and the Bioverativ spinoff, which will yield a return for investors when it happens early next year, could distract those investors from any signals that the company could be up for grabs.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Those signals include growth worries for the company’s MS franchise, whose recent star--oral med Tecfidera--ran into a slowdown last year. Since then, Biogen has leaned on consumer advertising to help rev things up, but forthcoming competition from Roche could leave the entire MS portfolio hurting, analysts have predicted.

Biogen is also expecting some change at the top, with CEO George Scangos ready to depart as soon as the Cambridge drugmaker names a successor. "The unusual announcement of the imminent departure of CEO George Scangos is certainly consistent with the company mounting a temporary 'For Sale' sign to acquirers," Leerink Partners analyst Geoffrey Porges wrote last week in a note to clients.

But even if Biogen can deflect the takeover talk, it doesn’t mean Bioverativ will want to do the same. And as brand-new Baxter spinoff Baxalta recently showed with its early-days sale to Shire, young companies can be swallowed without jeopardizing shareholders’ spinoff bounty--though it may take some legal maneuvering on the part of the acquirer to do so.

- read Biogen's release

Related Articles:
Biogen's not for sale, sources say--but if it were, who could afford it?
Is Biogen the latest big biotech M&A target? Allergan and Merck are circling, WSJ says
Biogen CEO Scangos to step down, raising questions about the Big Biotech's future
Biogen to spin off its hemophilia biz, focus on neuro drugs
Hard-hit Biogen needs to act fast, analysts say--or beware its deal-hungry peers

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.